Ionis Pharmaceuticals (NASDAQ: IONS) insider to sell 9,191 shares under Rule 144

Rhea-AI Filing Summary

An individual associated with Ionis Pharmaceuticals has filed a notice of proposed sale of restricted securities under Rule 144. The filer plans to sell 9,191 shares of Ionis common stock through Morgan Stanley Smith Barney on the NASDAQ, with an indicated aggregate market value of $700,602.62 at the time of the notice. Ionis had 161,137,930 common shares outstanding when this notice was prepared.

The shares to be sold are common stock acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, described as compensation. The planned sale date is listed as 01/16/2026. By signing the notice, the seller represents that they are not aware of any material adverse, non-public information about Ionis Pharmaceuticals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	9191	700602.62	161137930	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			9191	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Ionis Pharmaceuticals (IONS) Form 144 filing disclose?

The Form 144 discloses that a person associated with Ionis Pharmaceuticals intends to sell 9,191 shares of common stock under Rule 144 on the NASDAQ through Morgan Stanley Smith Barney.

How many Ionis Pharmaceuticals (IONS) shares are planned to be sold and what is their value?

The notice covers a proposed sale of 9,191 Ionis common shares with an aggregate market value of $700,602.62 at the time of the filing.

How were the Ionis Pharmaceuticals (IONS) shares being sold acquired?

The shares were acquired as RSUs granted under the 2011 Equity Incentive Plan, with the acquisition date listed as 01/15/2026 and characterized as compensation.

When is the planned sale date for the Ionis Pharmaceuticals (IONS) shares in this Form 144?

The approximate date of sale for the 9,191 common shares is listed as 01/16/2026.

On which exchange and through which broker will the Ionis (IONS) shares be sold?

The proposed sale is to be executed on the NASDAQ through Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036.

How many Ionis Pharmaceuticals (IONS) shares were outstanding at the time of this notice?

The notice states that 161,137,930 shares of Ionis common stock were outstanding at the time the information was provided.

What representation does the seller make in the Ionis (IONS) Form 144 notice?

By signing the notice, the seller represents that they do not know any material adverse information about Ionis Pharmaceuticals’ current or prospective operations that has not been publicly disclosed.